Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors

Published:2007 Issue:12 Volume:30 Page:2365-2370
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Shiose Yoshinobu¹,Ochi Yusuke²,Kuga Hiroshi³,Yamashita Fumiyoshi⁴,Hashida Mitsuru⁴

Affiliation:

1. Biological Research Laboratories IV, Daiichi Sankyo Co., Ltd., Kasai R&D Center

2. R&D Planning Department, Planning Group, Daiichi Sankyo Co., Ltd.

3. Development Research Department, Daiichi Sankyo Inc.

4. Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

http://www.jstage.jst.go.jp/article/bpb/30/12/30_12_2365/_pdf

Reference32 articles.

1. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

2. Liposomal formulations of cytotoxic drugs

3. Paclitaxel poliglumex (XYOTAX™, CT-2103): A macromolecular taxane

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action;Drug Metabolism and Pharmacokinetics;2024-06

2. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer;Nature Communications;2024-03-20

3. Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates;Biomedicines;2023-11-16

4. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response;Journal of Clinical Investigation;2023-09-15

5. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC;Future Oncology;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3